Premier Holding Corporation Announces Nearly 4,000 New Residential and Commercial Accounts in July for The Power Company, USA, LLC
ACCESSWIRE - Wed Aug 13, 7:16AM CDT
TUSTIN, CA / ACCESSWIRE / August 13, 2014 / Premier Holding Corp. (OTCQB: PRHL) (the "Company"
LiteOwl(TM) From Premier's Patented E-Series Demonstrates Energy-Saving Technology for Streetlights to City of Moreno Valley
Marketwire - Wed Jul 09, 7:02AM CDT
Premier Holding Corp. (http://www.prhlcorp.com) (OTCQB: PRHL) (the "Company"
Premier Holding Addresses Notable Response to Planned Entry Into Power Supplier Industry
Marketwire - Tue Jul 08, 7:25PM CDT
Premier Holding Corp. (http://www.prhlcorp.com) (OTCQB: PRHL) (the "Company"
Goldman Small Cap Research Issues Research Update On Premier Holding Corporation
PR Newswire - Tue Jul 08, 10:25AM CDT
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, announced today that it has released a new research update on Premier Holding Corporation (OTCQB: PRHL). Operating in the $500 billion+ deregulated energy industry sector, Premier Holding Corporation is set to become one of the few vertically integrated energy service providers.
Premier Holding Moves Closer to Adding a Third Energy Sector Subsidiary to Become an Energy Supplier and Provides New Pro Forma Estimates for 2015 Through 2018
Marketwire - Mon Jul 07, 4:33PM CDT
Premier Holding Corporation (OTCQB: PRHL) announces that it has produced detailed pro forma forecasts for the years 2015 through 2018 assuming the Company becomes a federally licensed energy supplier by FERC ("Federal Energy Regulatory Commission"
Premier Holding Corporation Announces Record High Quarterly Sales Numbers for The Power Company, USA, LLC
Marketwire - Wed Apr 02, 7:46AM CDT
Premier Holding Corporation (OTCQB: PRHL) today announced that its subsidiary, The Power Company, USA, LLC (TPC) set a new sales record, more than doubling its sales from door-to-door residential efforts in Q1 of 2014 vs Q1 of 2013. In the first quarter of 2013, the company completed 2,907 door-to-door residential sales of deregulated power and as of the close of the first quarter this year, that number is an astounding 7,291 new contracts.
Premier Holding Corp. Interview at FSXinterlinked Conference for the Interlinked Investment News Channel on InterlinkedTV
PRWeb - Tue Mar 25, 1:56PM CDT
Premier Holding Corporation was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Dallas, Texas.
Premier Holding Corporation Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV
PRWeb - Mon Mar 24, 1:22PM CDT
Premier Holding Corporation, was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Dallas, Texas.
Premier Holding Corporation Announces a Signed Letter of Intent With PDC Capital Group LLC, to Raise up to 25 Million Dollars
Marketwire - Thu Mar 13, 12:00PM CDT
Premier Holding Corporation (OTCQB: PRHL) today announced that it has received a signed Letter of Intent from PDC Capital Group LLC, (PDC) to fund the company up to $25 million. PDC is highly confident that it can raise between $5 million and $25 million in EB5 funds for PRHL utilizing its international resources.
Randall Letcavage Receives Glowing Reviews at FSX Investment Conference in Dallas
Marketwire - Mon Mar 10, 2:00PM CDT
FSXInterlinked (formerly Financial Services Exchange), the premiere investment conference organization in the United States, has announced that for the second time, Randall Letcavage, President and CEO of Premier Holding Corporation (OTCQB: PRHL) spoke at their FSXInterlinked Investment Conference held in Dallas, Texas from February 12-14th, 2014. This was their 122nd consecutive quarterly conference.
Global Rheumatoid Arthritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 2:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/59mmkd/pharmapoint) has announced the addition of the "PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis Event-Driven Update" report to their offering. Rheumatoid Arthritis Researchers Limber Up RA drug sales in 2012 will reach over $15.5 billion across the US, the UK, France, Germany, Italy, Spain, Japan, China, India and Australia, reaching over $21 billion by 2022. Upcoming therapeutics and an emerging biosimilars industry will improve the lives of Rheumatoid Arthritis (RA) sufferers around the world, claims a new report by healthcare experts. The chronic autoimmune disease, which causes inflammation and deformity of the joints, forces nearly 50% of patients to give up work during the first decade following diagnosis due to the physical, emotional, and financial burdens of the condition. The estimated direct and indirect cost of RA therapy in the US in 2011 alone reached close to $19 billion. The disease therefore represents a huge personal and social burden, making its treatment of paramount importance. Abbott has been a dominant player in the RA market due to the success of Humira (adalimumab), but the drug is faced with a looming patent expiry, which will see Abbott's sales start to slip. Humira does have a loyal following and looks likely to maintain the lion's share of the market in 2022, but Abbott's lack of RA pipeline products suggests that the company's RA fortunes will fade. Many RA drugs such as Humira already offer patients good safety and efficacy profiles, and current R&D efforts therefore aim to offer something new to the market - oral administration, more convenient dosing frequencies, novel mechanisms of action (MOA), or improved drug availability based on formulations. Upcoming pipeline products include Pfizer's first-in-class JAK3 inhibitor tofacitinib, which offers a novel MOA and oral formulation, Eli Lilly's first-in-class anti-BAFF (B-cell activating factor) compound tabalumab, and Rigel Pharmaceuticals/AstraZeneca spleen tyrosine kinase (SYK) inhibitor (AZ) oral treatment, fostamatinib. These compounds will challenge current biologics, and attempt to dislodge the market dominance of TNF inhibitors, if their safety and efficacy profiles are proven. The emergence of biosimilars will also provide alternatives to current biologics, and hopefully at a lower cost. The impending arrival of biosimilars is predicted for many markets, including the US, who are anticipated to finalize a biosimilar approval pathway in time for the patent expiration of Remicade and Actemra in 2015. However, emerging markets present a challenge for companies producing RA biologics. While these countries represent a potential source of massive sales growth, there is increasing pressure in these markets to provide cost-effective drug access, and both India and China have been manufacturing and selling biosimilars for top-selling RA therapies despite the protests of Big Pharma against patent infringement. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Abbott - Pfizer - Amgen - Johnson & Johnson - Eli Lilly - Bristol-Myers Squibb (BMS) - UCB - Roche - GlaxoSmithKline For more information visit http://www.researchandmarkets.com/research/59...harmapoint
Probe Manufacturing wins manufacturing contract from Muni-Fed Energy
M2 - Thu Feb 20, 4:39AM CST
Probe Manufacturing Inc (OTC QB
Probe Manufacturing Chosen by Muni-Fed Energy to Manufacture Premier Holdings Proprietary Lighting Efficiency Technology
Business Wire - Wed Feb 19, 9:30AM CST
Probe Manufacturing, Inc., (OTC QB: PMFI) ("Probe" or "the Company"
Premier Holding Corporation Announces The Power Company Is Opening Additional Sales Offices in Maryland
Marketwire - Thu Jan 23, 9:28PM CST
Premier Holding Corporation (OTCQB: PRHL) today announced that its subsidiary, The Power Company (TPC) is increasing its Maryland presence by opening additional offices in the Baltimore area. This will increase its presence in both the residential and commercial markets throughout Maryland.
Premier Holding Corporation Announces Its R&D Initiative to Meet California's New Title 24 Requirements
Marketwire - Thu Jan 23, 7:31AM CST
Premier Holding Corporation (OTCQB: PRHL) today announced that it has launched a new R&D initiative for its proprietary E-Series technology allowing for tri-level switching of HID lights. This new switching technology has been successfully demonstrated to corporate leadership allowing the E-Series technology to be controlled by an external sensor, such as a photocell or motion detector, that automatically adjusts the lighting levels to switch between six setting for HID lights, exceeding the standards set forth in California's newly revised Title 24 (of three savings settings). Further, the product, due to its modular design can allow different lighting circuits to perform at different intensities, providing an extra level of control and efficiency.